Izrael - hebrejščina - Ministry of Health

roche pharmaceuticals (israel) ltd - emicizumab - תמיסה להזרקה - emicizumab 150 mg / 1 ml - emicizumab

Izrael - hebrejščina - Ministry of Health

roche pharmaceuticals (israel) ltd - emicizumab - תמיסה להזרקה - emicizumab 30 mg / 1 ml - emicizumab

Izrael - hebrejščina - Ministry of Health

bristol, myers squibb (israel) limited, israel - fedratinib as dihydrochloride monohydrate - קפסולות - fedratinib as dihydrochloride monohydrate 100 mg - fedratinib

Izrael - hebrejščina - Ministry of Health

roche pharmaceuticals (israel) ltd - trastuzumab - תמיסה לאינפוזיה - trastuzumab 440 mg/ml - trastuzumab - trastuzumab - herceptin is indicated for the treatment of patients with metastatic breast cancer who have tumours that overexpress her2: 1. as a single agent for the treatment of those patients who have received one or more chemotherapy regiments for their metastatic disease. 2. in combination with paclitaxel or docetaxel for the treatment of those patients who have not received chemotherapy for their metastatic disease. 3. herceptin in combination with an aromatase inhibitor for the treatment of postmenopausal patients with hormone-receptor positive metastatic breast cancer. early breast cancer (ebc) :herceptin is indicated to treat patients with her2-positive early breast cancer following surgery and chemotherapy (neoadjuvant or adjuvant) either alone or in combination with chemotherapy excluding anthracyclines. herceptin should only be used in patients whose tumors have either her2 overexpression or her2 gene amplification as determined by an accurate and validated assay.her2 metastatic gastric cancer (mgc)herceptin in

Izrael - hebrejščina - Ministry of Health

pfizer pfe pharmaceuticals israel ltd - exemestane - טבליות מצופות - exemestane 25 mg - exemestane - exemestane - aromasin is indicated for the treatment of advanced breast cancer (abc) in women with natural or induced postmenopausal status whose disease has progressed following anti-oestrogen therapy alone. aromasin is also indicated for the treatment of postmenopausal women with abc whose disease has progressed following multiple hormonal therapies. aromasin is indicated for the adjuvant treatment of postmenopausal women with oestrogen receptor positive invasive early breas cancer following 2-3 years of initial adjuvant tamoxifen therapy.

Izrael - hebrejščina - Ministry of Health

pfizer pharmaceuticals israel ltd - sirolimus - תמיסה (פומי) - sirolimus 1 mg/ml - sirolimus - sirolimus - rapamune is indicated for the prophylaxis of organ rejection in adult patients at low to moderate immunological risk receiving a renal transplant. it is recommended that rapamune be used initially in combination with cyclosporine microemulsion and corticosteroids for 2 to 3 months. rapamune may be continued as maintenance therapy with corticosteroids only if cyclosporine can be progressively discontinued.

Izrael - hebrejščina - Ministry of Health

pfizer pharmaceuticals israel ltd - sirolimus - טבליות מצופות - sirolimus 1 mg - sirolimus

Izrael - hebrejščina - Ministry of Health

pfizer pharmaceuticals israel ltd - sirolimus - טבליות מצופות - sirolimus 1 mg - sirolimus

Izrael - hebrejščina - Ministry of Health

pfizer pharmaceuticals israel ltd - sirolimus - תמיסה (פומי) - sirolimus 1 mg/ml - sirolimus

Izrael - hebrejščina - Ministry of Health

pharmalogic ltd - heparin sodium - תמיסה להזרקה\אינפוזיה - heparin sodium 5000 iu/ml - heparin - heparin - treatment of thrombo-embolic disorders as deep vein thrombosis, acute arterial embolism or thrombosis, thrombophlebitis, pulmonary embolism , fat embolism. prophylaxis of deep vein thrombosis and thromboembolic events.